181 related articles for article (PubMed ID: 8943866)
21. Chromosome abnormalities in secondary myelodysplastic syndromes.
Bloomfield CD
Scand J Haematol Suppl; 1986; 45():82-90. PubMed ID: 3515525
[No Abstract] [Full Text] [Related]
22. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.
Wattel E; Preudhomme C; Hecquet B; Vanrumbeke M; Quesnel B; Dervite I; Morel P; Fenaux P
Blood; 1994 Nov; 84(9):3148-57. PubMed ID: 7949187
[TBL] [Abstract][Full Text] [Related]
23. [Therapy-related acute leukemia: study of 23 pacients].
Motlló C; Sancho JM; García O; Granada I; Millá F; Ribera JM
Med Clin (Barc); 2011 Oct; 137(10):449-52. PubMed ID: 21696789
[TBL] [Abstract][Full Text] [Related]
24. [Therapy-induced leukemia -- an underestimated complication of antineoplastic chemotherapy?].
Dührsen U
Zentralbl Gynakol; 2005 Aug; 127(4):235-41. PubMed ID: 16037905
[TBL] [Abstract][Full Text] [Related]
25. Incidence and susceptibility to therapy-related myeloid neoplasms.
Leone G; Fianchi L; Pagano L; Voso MT
Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
[TBL] [Abstract][Full Text] [Related]
26. Therapy-related leukemia and myelodysplasia: susceptibility and incidence.
Leone G; Pagano L; Ben-Yehuda D; Voso MT
Haematologica; 2007 Oct; 92(10):1389-98. PubMed ID: 17768113
[TBL] [Abstract][Full Text] [Related]
27. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
Smith SM; Le Beau MM; Huo D; Karrison T; Sobecks RM; Anastasi J; Vardiman JW; Rowley JD; Larson RA
Blood; 2003 Jul; 102(1):43-52. PubMed ID: 12623843
[TBL] [Abstract][Full Text] [Related]
28. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
29. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
[TBL] [Abstract][Full Text] [Related]
30. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
Gale RP; Hlatky L; Sachs RK; Radivoyevitch T
Leuk Res; 2014 Oct; 38(10):1162-4. PubMed ID: 25175829
[No Abstract] [Full Text] [Related]
31. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
[TBL] [Abstract][Full Text] [Related]
32. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.
Levine EG; Bloomfield CD
Semin Oncol; 1992 Feb; 19(1):47-84. PubMed ID: 1736370
[TBL] [Abstract][Full Text] [Related]
33. The incidence of secondary leukemias.
Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
[TBL] [Abstract][Full Text] [Related]
34. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
35. Therapy-related myeloid leukemia.
Thirman MJ; Larson RA
Hematol Oncol Clin North Am; 1996 Apr; 10(2):293-320. PubMed ID: 8707757
[TBL] [Abstract][Full Text] [Related]
36. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
[TBL] [Abstract][Full Text] [Related]
37. Therapy-induced myelodysplasia and secondary leukaemia.
Frisch B; Bartl R; Chaichik S
Scand J Haematol Suppl; 1986; 45():38-47. PubMed ID: 3457445
[No Abstract] [Full Text] [Related]
38. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation.
Pedersen-Bjergaard J; Andersen MK; Christiansen DH
Blood; 2000 Jun; 95(11):3273-9. PubMed ID: 10828005
[TBL] [Abstract][Full Text] [Related]
39. The heterogeneity of leukemia occurring after treatment for sarcoma.
Varterasian M; Zalupski M; Karanes C
Am J Clin Oncol; 1997 Dec; 20(6):585-6. PubMed ID: 9391546
[TBL] [Abstract][Full Text] [Related]
40. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Gillis NK; Ball M; Zhang Q; Ma Z; Zhao Y; Yoder SJ; Balasis ME; Mesa TE; Sallman DA; Lancet JE; Komrokji RS; List AF; McLeod HL; Alsina M; Baz R; Shain KH; Rollison DE; Padron E
Lancet Oncol; 2017 Jan; 18(1):112-121. PubMed ID: 27927582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
